1. Home
  2. STKS vs VERU Comparison

STKS vs VERU Comparison

Compare STKS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The ONE Group Hospitality Inc.

STKS

The ONE Group Hospitality Inc.

N/A

Current Price

$1.09

Market Cap

48.8M

ML Signal

N/A

Logo Veru Inc.

VERU

Veru Inc.

N/A

Current Price

$2.12

Market Cap

41.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STKS
VERU
Founded
2004
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.8M
41.9M
IPO Year
2011
1996

Fundamental Metrics

Financial Performance
Metric
STKS
VERU
Price
$1.09
$2.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
3
Target Price
$4.25
★ $25.67
AVG Volume (30 Days)
33.6K
★ 145.2K
Earning Date
11-04-2026
12-16-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $805,722,000.00
$16,296,958.00
Revenue This Year
$0.51
N/A
Revenue Next Year
$7.92
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 19.66
N/A
52 Week Low
$0.97
$2.04
52 Week High
$2.65
$7.33

Technical Indicators

Market Signals
Indicator
STKS
VERU
Relative Strength Index (RSI) 43.68 40.24
Support Level $1.07 N/A
Resistance Level $1.99 $2.68
Average True Range (ATR) 0.13 0.11
MACD 0.01 -0.00
Stochastic Oscillator 40.43 18.18

Price Performance

Historical Comparison
STKS
VERU

About STKS The ONE Group Hospitality Inc.

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: